Tag:
Viibryd
Latest Headlines
Latest Headlines
Forest profits reel as Lexapro faces first copycats
The company's profits plummeted 40% as its blockbuster antidepressant Lexapro fell off patent.
M&A fills patent holes, fuels geographic expansion
Three deals now in the works embody three very different trends. Yet another Japanese drugmaker is expanding westward by snapping up a smaller pharma company. A U.S. company is buying a
Forest Labs swallows Clinical Data pill in $1.2B buyout
Just weeks after Clinical Data ( $CLDA ) won a surprising approval for a new antidepressant, Forest Laboratories has swept in to buy the biotech for $1.2 billion, paying $30 a share plus a CVR that
Clinical Data hires reps for Viibryd launch
Now that Clinical Data has an FDA approval in hand, it's gearing up to grab a piece of the $12 billion antidepressant market. The company is hiring sales reps and rolling out a marketing campaign to
